Gerardo Turcatti

Gerardo Turcatti is an Adjunct Professor at the School of Life Sciences (EPFL), leading the Biomolecular Screening Facility (BSF) and the Biomolecular Screening Core Facility. He holds roles in SSV-Teaching and directs the ACCESS program under the NCCR-Chemical Biology initiative. With a Master's in Chemical Engineering (University of Geneva) and a PhD in Chemistry and Biochemistry (EPFL, where he won the best doctoral thesis award), his expertise spans multidisciplinary R&D in drug screening, chemical biology, and bio-analytical chemistry.

His research focuses on high-throughput screening technologies, including holographic imaging for cardiomyocyte dynamics and red blood cell storage studies. He has pioneered platforms for malaria drug discovery and cancer therapeutics, leveraging 3D tumoroid models and combinatorial chemistry. His work extends to antiviral research, including SARS-CoV-2 inhibitors and canine distemper virus studies, and includes innovations in nucleic acid sequencing technologies through his former role as CTO of Manteia S.A.

• Key Projects: ACCESS platform, BSF facility, Next-Gen sequencing tech development
• Teaching: Leads the 'Methods: from disease models to therapy' course, integrating hands-on platform rotations in life sciences
• Labs/Teams: Directs EPFL's Biomolecular Screening Facility and collaborates with industry and academic partners

Publications emphasize translational applications, including drug repurposing, cardiovascular toxicity screening, and red blood cell storage optimization. His contributions bridge academic research and industrial innovation, with over 100 peer-reviewed articles and patents in chemical biology and drug discovery.